About Interactor protein for cytohesin exchange factors 1
Interactor protein for cytohesin exchange factors 1 (IPCEF1) is a protein
from Homo sapiens identified by UniProt accession
Q8WWN9, 437 residues long.
MolForge cross-references it against 0 known binders and
43 disease associations.
Target properties
| Protein name | Interactor protein for cytohesin exchange factors 1 |
| UniProt accession | Q8WWN9 |
| Gene | IPCEF1 |
| Organism | Homo sapiens |
| Length | 437 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (43)
Diseases linked to this target (Open Targets).
- response to tramadol · score 0.52
- DNA methylation · score 0.33
- atopic asthma · score 0.33
- systemic lupus erythematosus · score 0.33
- chronic lymphocytic leukemia · score 0.28
- neurodegenerative disease · score 0.27
- asthma · score 0.18
- inflammatory bowel disease · score 0.13
- IGF-1 measurement · score 0.09
- diastolic blood pressure · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8WWN9-F1 | alphafold | PREDICTED | 64.04 | — |
Amino-acid sequence (437 residues)
MTSYMAIDGS ALVPLRQKPR RKTQGFLTMS RRRISCKDLG HADCQGWLYK KKEKGSFLSN KWKKFWVILK GSSLYWYSNQ MAEKADGFVN LPDFTVERAS ECKKKHAFKI SHPQIKTFYF AAENVQEMNV WLNKLGSAVI HQESTTKDEE CYSESEQEDP EIAAETPPPP HASQTQSLTA QQASSSSPSL SGTSYSFSSL ENTVKTPSSF PSSLSKERQS LPDTVNSLSA AEDEGQPITF AVQVHSPVPS EAGIHKALEN SFVTSESGFL NSLSSDDTSS LSSNHDHLTV PDKPAGSKIM DKEETKVSED DEMEKLYKSL EQASLSPLGD RRPSTKKELR KSFVKRCKNP SINEKLHKIR TLNSTLKCKE HDLAMINQLL DDPKLTARKY REWKVMNTLL IQDIYQQQRA SPAPDDTDDT PQELKKSPSS PSVENSI
Explore Interactor protein for cytohesin exchange factors 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets